11,940 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,940 shares of the biopharmaceutical company's stock, valued at approximately $1,103,000.

Other hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $0.80 during mid-day trading on Wednesday, reaching $104.88. The company had a trading volume of 7,105,079 shares, compared to its average volume of 7,494,391. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market cap of $130.59 billion, a price-to-earnings ratio of 283.46, a PEG ratio of 0.71 and a beta of 0.32. The company has a 50 day moving average of $108.63 and a 200-day moving average of $97.11. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.01%. Gilead Sciences's payout ratio is currently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent research reports. Piper Sandler increased their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 300,285 shares of company stock worth $30,274,875. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.